OpenAI is no different
That's not exactly true. OpenAI is structured like Mozilla, where there's a nonprofit parent part which owns a for-profit subsidiary.
Idk all the details, but I suspect that the typical exit strategy isn't in the cards for them without some legal shenanigans.
Cue the legal bickering over what counts as "reasonable". I think the definition is clear: the only reasonable price for medicine is the lowest possible price. And the only way to ensure that is to not award drug patents in the first place (at all, but especially if development was funded by taxpayers).